Drugs / Human Regular U-500 Insulin
Human Regular U-500 Insulin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02561078 | Oct 2015 → May 2017 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT01774968 | Feb 2013 → May 2014 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human regular U-500 insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02561078 ↗ |
| Modality | Protein / enzyme biologic | “human regular U-500 insulin” NCT01774968 ↗ |
| Route | Subcutaneous | “administered subcutaneously (SC)” NCT01774968 ↗ |